OUR WORK
Working with Artrya to build Salix.
Introduction to Artrya
Vision
Artrya is a MedTech company, on a mission to help save lives through supporting clinicians with the rapid detection of coronary artery disease (CAD) using Artificial Intelligence (AI).
Coronary artery disease diagnosis has not advanced significantly in the last 50 years. Worldwide, 126 million people are affected by CAD, which leads to 9 million deaths every year. The majority of those have no warning symptoms until the disease is far advanced
Artrya saw the opportunity to positively disrupt the traditional model of diagnosing CAD, by enabling fast and accurate reporting of high-risk imaging biomarkers, and empowering clinicians to be better informed when making diagnoses.
Salix
Artrya began developing Salix in 2019, in collaboration with the University of Western Australia and the Harry Perkins Institute of Medical Research.
Salix assists clinicians by rapidly reviewing CT scan data using the power of AI. It also integrates with existing systems to optimise clinical workflows and, being browser-based, Salix requires no upfront capital expenditure.
This means clinicians will be armed to make a fast and accurate diagnosis, guiding patients to optimal preventative therapy in a timely manner.
This has the potential to allow diagnostic imaging clinics to benefit from lower costs and fast analysis to serve patients and to increase revenue through treating more patients than previously possible. By aiming to reduce the impact of major cardiac events across the population, health systems as a whole may benefit through reduced treatment costs and resource utilisation.
Road to MVP
Artrya’s immediate challenge was to translate their innovative research into a commercial product that would be game-changing for the medical community and attract funding support from the private capital community.
The challenge was doubled by the need for a rapid development to maintain vital momentum.
At the time of partnership, Artrya’s internal team, being a small group of world-class experts in research and development, asked Hatchd to collaborate and implement Artrya’s product vision.
A squad of highly skilled specialists, drawn from Hatchd and its sister company, Adapptor, was rapidly deployed, working alongside and as a seamless extension of the Artrya development team. The proof-of-concept prototype was picked up and taken down the path of transformation into a minimum viable product.
To achieve a complex product vision, with time-to-market in mind, Artrya’s needs extended to design and product management, so Hatchd brought in the necessary reinforcements to bolster capabilities.
As a full product team, we were able to work with Artrya’s core team to crystallise a product development plan. This involved regular consultations with stakeholders to understand requirements and validating design concepts and functionality with early Salix users.
Our product management team, alongside Artrya’s project manager, facilitated productive collaboration between researchers, designers and developers, ensuring that sprints were organised and effective.
Within a short period of time, the blended Artrya and Hatchd teams delivered a limited first release to a closed audience of clinicians. This release successfully demonstrated Salix’s value and provided investors with confidence in the future of the product, and as such funding exceeded expectations.
Regulatory Compliance and Product Validation
With its core functionality and innovative IP validated in the first release, for the next iteration of Salix the team set its sights on ensuring feature parity with the current market alternatives.
The Hatchd designers and developers continued to operate as an extension of the Artrya team, strengthening the already firm relationship. Together we worked to develop clarity around the key needs and functionality required to develop a solution that truly solves a critical problem in CAD diagnosis today.
Through efficient sprint cycles, features were designed and developed that enabled Salix to compete with and surpass the offering of the current generation of products.
The challenge of ensuring that everything is always working as intended increases with product complexity, especially so when the product is subject to stringent compliance regulations.
Rigorous testing of every feature and release, along with continuous 'smoke' testing during development is an absolute requirement of maintaining product quality. Hatchd & Adapptor provides this service to Artrya through an experienced team of in-house testers, making sure there are no unwelcome surprises on release day.
Clinicians' feedback was increasingly positive as Salix evolved to meet a growing set of their needs and, through the submissions driven by Artrya’s Regulatory Affairs Manager, has achieved listing on the Australian Register of Therapeutic Goods (ID 347719).
Growing the company while scaling the product concept.
Infrastructure for scale
With a feature roadmap firmly in place, focus shifted towards optimising software performance in anticipation of servicing clients at scale.
Cloud-based web services offer numerous competitive benefits in a field crowded with expensive on-premise solutions. Our savvy combined team worked together to overcome the previously accepted limitations of SAAS architecture, refactoring Salix’s browser-based approach until its performance reached real-time responsiveness, comparable to hardware-dependent solutions.
Supporting team growth
Hatchd’s role is to help the Artrya product team become self-sufficient as soon as possible. However, building a product team takes time, and the transition from a tiny founding team to a listed company, while building a product, brings its own challenges.
This is a delicate time in any start-up's journey and requires a unique kind of support from a design and technology partner. Our T-shaped specialists spanning across the disciplines of design, development, testing and product management are available to bridge any capability gaps during that journey.
The team also plays an important role in the onboarding of new Artrya employees. As the pace of recruitment accelerates, Hatchd is flexible enough to make room for the new recruits and support them as they find their feet in their roles.
Great success
On 26 November 2021 Artrya listed on the ASX, generating $40m+ in IPO funding. It is now running product pilots in a few practices across Australia, international expansion is in discussion and rapid team growth is occurring. We have had the great pleasure to be a part of the inspiring Artrya adventure.
Find out more about Artrya at www.artrya.com